Medicines Law & Policy

Medicines Law & Policy brings together legal and policy experts in the field of access to medicines, international law, and public health. We provide policy and legal analysis, best practice models and other information that can be used by governments, non-governmental organisations, product development initiatives, funding agencies, UN agencies and others working to ensure the availability of effective, safe and affordable medicines for all.

Articles from this Author

Transfer of Technology: New definition and stronger language needed

Getting to a meaningful agreement: ML&P’s opening statement to the 12th round of pandemic accord negotiations

MSF’s Access Campaign is an invaluable actor in global health; shutting it down is short-sighted.

Pressure from European countries related to the use of TRIPS Flexibilities

European Parliament’s amendments make the Regulation for EU-wide compulsory licensing difficult to use and need to be rolled back

Intervention at Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response, 9th...

Commission report on competition enforcement in the pharmaceutical sector

ML&P’s Statement at the Intergovernmental Negotiating Body on a pandemic accord

Medicines Law & Policy

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.

This work is licensed under Creative Commons. You are free to share, with attribution and without changes, for non-commercial purposes.

Technical Briefing Papers

Our Work on Covid-19

Our Blog

The TRIPS Flexibilities Database